
CGMs & Non-Insulin-Treated T2D, Islet Autoantibody Screening & T1D, Semaglutide CVD Risk Reduction, and more!
Welcome to the latest episode (November 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Updates: Oser, et al. Continuous Glucose Monitoring in Non–Insulin-Treated Type 2 Diabetes. New England Journal of Medicine. October 2026; doi.org/10.1056/NEJMoa2608571 Islet autoantibody screening identifies early-stage type 1 diabetes across Europe, Need-To-Know Institute press release Yang, et al. Sodium-Glucose Cotransporter 2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and Erythropoiesis. JAMA. Published online October 2026. doi.org/10.1001/jama.2026.19921 Jastreboff, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. September, 2026. doi.org/10.1056/NEJMoa2604169 Bellido, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. The Lancet. Volume 408, Issue 10563. doi.org/10.1016/S0140-6736(26)01861-1 Colhoun, et al. Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial. European Heart Journal. 2026; ehag524, doi.org/10.1093/eurheartj/ehag524 Garvey, et al. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial.
Publisher
DOC Updates
Link
diabetescoreupdate.libsyn.com/cgms-non-insulin-treated-t2d-islet-autoantibody-screening-t1d-semaglutide-cvd-risk-reduction-and-more
Published
October 29, 2026
Duration
32 min
Format
Podcast
Category
Lifestyle · Medicine
Source
RSS feed
Host
American Diabetes Association
DOC Updates
@docupdates
#treatedt2d #isletautoantibodyscreening #semaglutidecvdrisk #medicine
